March 13th 2024
Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
February 18th 2024
February 13th 2024
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
ctDNA May Predict Chemo Efficacy in Stage II/III Colorectal Cancer
January 21st 2024Disease-free survival benefits with chemotherapy appears to be more prominent in patients with colorectal cancer who are minimal residual disease–positive compared with those minimal residual disease–negative disease.
Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer
January 20th 2024Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Efficacy Improvement Observed in Nivolumab Combo in Advanced GI Cancers
January 18th 2024Results from an observational study found nivolumab plus chemotherapy helped enhance overall survival and progression-free survival for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Pembrolizumab Improves Responses but Not EFS in Locally Advanced Gastric Cancer
December 27th 2023Investigators indicate that, although treatment with adjuvant/neoadjuvant pembrolizumab results in an absolute decrease in risk of an event, the benefit was not statistically significant in those with untreated, locally advanced gastric/GEJ cancer.
Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers
December 18th 2023In Europe, pembrolizumab is now available as a treatment in combination with fluoropyrimidine-/platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, as well as in combination with gemcitabine/cisplatin for locally advanced biliary tract carcinoma.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.